No statistically significant differences in PFS occurred between bevacizumab and linifanib doses ( low , hazard ratio -LSB- HR -RSB- , @ -LSB- @ % confidence interval -LSB- CI -RSB- , @-@ @ -RSB- ; high , HR , @ -LSB- @ % CI , @-@ @ -RSB- ) .